Clearmind Medicine provided an update from its ongoing first-in-human Phase I/IIa trial of CMND-100 for alcohol use disorder, with principal investigators from Yale and Johns Hopkins conveying a generally positive early impression. The investigators highlighted the non-hallucinogenic profile of MEAI, which differentiates it from classical psychedelics and could enable a simpler treatment model without hospitalization or intensive monitoring. Recruitment has progressed well despite strict eligibility criteria, and a promising early safety profile has been observed with no meaningful adverse effects or cardiac safety concerns to date. The study is evaluating CMND-100, Clearmind's novel non-hallucinogenic compound, in a trial that is part of the company's broader neuroplastogen-derived therapeutics pipeline.
Clearmind Medicine Inc. Common SharesPositive early safety and non-hallucinogenic profile from Phase I/IIa trial of CMND-100 for alcohol use disorder.